Saldívar RD, Vázquez J, Lara R, Ramos C, Lira J, Rodríguez E, Romo J

Language: Spanish
References: 15
Page: 559-567
PDF size: 433.11 Kb.

ABSTRACT

Background: The combined oral contraceptives are one of the most prescribed medicines. Across the years they have given to more than 60 million women of the whole world a suitable method for the highly reliable and effective natal control. The oral contraceptives are different from other medicines; principally they are not in use for controlling any disease and have the potential of giving advantages.
Objectives: To evaluate the control of the cycle, tolerability and acceptance of an oral contraceptive of ultralow dose with gestodene (60 µg) and ethinylestradiol (15 µg) in a population of healthy women from 18 to 35 years.
Participants and methods: The study included adult healthy women, all the users signed assent of informed before being included to the study and of the beginning of any procedure in agreement with the declarations of Helsinki and its amendments. Descriptive statistics was used for the demographic information and the comparison between the initial and final visits of the variables of efficiency. There was used the test (Proof) of ranges of Wilcoxon’s sign for related samples.
Results: There were included 113 women. The average of age was 26.08 years (SD = 4.43), weight of 62.02 kg (SD = 11.13) and height of 159.20 cm (SD = 6.06). The distribution in four centers was: 32 in the University Hospital (Monterrey), 21 in the Country 2000 (Guadalajara), 30 in in the Medical Center La Mora (Aguascalientes) and 30 in Perinatology National Institute (Mexico City).
Conclusions: The contraceptive efficiency of the combination of 15 µg of ethinylestradiol and 60 µg of gestodene has been demonstrated in previous studies. This study ratifies the international results of efficiency and tolerability.

REFERENCES

1. Gestodene Study Group 322. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 µg and ethinylestradiol 15 µg. Eur J Contracep Reprod Health Care, Vol 4 (Suppl 2): 9-15, Nov 1999

2. Archer DF, Maheux R, DelConte A, O’Brien FB. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 µg levonorgestrel and 20 µg ethinylestradiol (Alesse). Am J Obstet Gynecol 1999;181(5 pt 2):39-44.

3. Boerrigter PJ, Hellman H, Dolker M. International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 µg and ethinylestradiol 20 µg. Clin Ther 1999;21:118-27.

4. Poindexter A. The emerging use of the 20-µg oral contraceptive. Fertil Steril 2001;75:457-65.

5. Thiboutot D, Archer DF, Lemay A, Washenik K, et al. A randomized, controlled trial of a low-dose contraceptive containing 20 µg of ethinyl estradiol and 100 µg of levonorgestrel for acne treatment. Fertil Steril 2001;76:461-8.

6. Speroff L. A clinical guide for contraception. 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 2001.

7. Fruzzetti F, Genazzani AR, Ricci C, De Nigri F, et al. A 12 month clinical investigation with a 24-day regimen containing 15 µg ethinylestradiol plus 60 µg gestodene with respect to hemostasis and cycle control. Contraception 2001;63:303-7.

8. Caruso S, Agnello C, Intelisano G, Farina M, et al. Sexual behavior women taking low-dose oral contraceptive containing 15 µg ethinylestradiol/60 µg gestodene. Contraception 2004;69:237-40.

9. Hite RC, Bannemerschult R, Fox-Kuchenbecker P, Turck R, Brill K. Large observational trial of a new low-dose oral contraceptive containing 20 µg of ethynilestradiol and 100 µg levonorgestrel (Miranova) in Germany. Eur J Contracep Reprod Health Care 1999;4:7-13.

10. DelConte A, Loffer F, Grubb GS. Cycle control with oral contraceptives containing 20 micrograms of ethinyl estradiol. A multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 micrograms/20 micrograms) and norethindrone/ethinyl estradiol (1000 micrograms/20 micrograms). Contraception 1999;59(3):187-93.

11. Rosenberg MJ. Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation. Contraception 1995;51:283-8.

12. Endrikat J, Gerlinger C, Cronin M, Wessel J, et al. Body weight changes during use of a oral monophasic oral contraceptive containing 20 µg ethinylestradiol and 75 µg gestodene with comparison of the women who completed versus those who prematurely discontinued intake. Eur J Contracep Reprod Health Care 2001;6:199-204.

13. Rosenberg M. Weight changes with oral contraceptive use and during the menstrual cycle. Contraception 1998;58:345-9.

14. Gallo MF, Grimes DH, Schulz KF, Helmerhost FM. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol 2004;103:359-73.

15. Martín del Campo A, et al. Construcción de la Escala de Perfil Afectivo. Salud Mental 1995;19(Supl).